Spravato therapy for Treatment Resistant Depression

Ketamine, traditionally known as an anesthetic, has gained attention in recent years for its rapid and robust antidepressant effects, particularly in individuals with treatment-resistant depression (TRD). Spravato (esketamine) nasal spray is a medication derived from ketamine that has been FDA-approved for the treatment of TRD.

General Information:

• Ketamine works differently from traditional antidepressants by targeting the brain’s glutamate system, leading to rapid improvements in depressive symptoms.
• Spravato is administered as a nasal spray under the supervision of a healthcare provider, typically in a clinic setting.
• Treatment with Spravato is typically initiated with twice-weekly sessions for the first month, followed by weekly or bi-weekly maintenance doses as needed.

Statistics:

• According to the National Institute of Mental Health (NIMH), approximately one-third of individuals with major depressive disorder do not respond adequately to standard antidepressant medications.
• Clinical trials have shown that Spravato can lead to significant reductions in depressive symptoms within hours or days, compared to weeks or months with traditional antidepressants.

Resources:

• National Alliance on Mental Illness (NAMI): NAMI offers resources and support for individuals living with depression, including information on treatment options and peer support groups.
• American Psychiatric Association (APA): The APA provides guidelines and resources for healthcare providers regarding the use of ketamine/Spravato therapy in the treatment of TRD.